This pressure has weighed on Lilly stock from time to time, particularly after Novo became the first to win approval for a ...

Mounjaro and Zepbound are driving Eli Lilly's earnings sharply higher. Foundayo looks like another top-seller. Eli Lilly's ...

Lilly hiked its full-year sales outlook by $2 billion, and also raised its adjusted profit guidance.

By Christy Santhosh and Mrinalika Roy April 30 (Reuters) - Eli Lilly hiked its full-year profit and revenue forecasts on ...

Surging consumer demand for blockbuster weight-loss drugs helped offset their declining prices.

Eli Lilly (LLY) has cemented its status as the world's leading pharmaceutical company as it produced a stellar set of Q1 2026 ...

Obesity drug giant Eli Lilly on Thursday reported a monster first quarter, fortifying our conviction to stick with the stock ...

A boil water notice has been issued for the following county roads 843, 845, 846, 847, 848, 849 ...

Eli Lilly (LLY) stock jumps as the company raised its full-year outlook alongside better-than-expected Q1 2026 financials ...

As Eli Lilly gets off to the races with the launch of its flagship oral GLP-1 Foundayo, the Indianapolis drugmaker—and at ...

The Food and Drug Administration proposed excluding Novo Nordisk and Eli Lilly's weight-loss drugs from a key compounding ...

By Christy Santhosh May 1 (Reuters) - Eli Lilly's newly launched oral weight-loss drug, Foundayo, was prescribed 5,612 times ...